Please login to the form below

Not currently logged in

Unlock the power of data to realise strategic goals

by Lisa Alderson

With so much data available, identifying the right blend of information and optimising its potential to shape the go-to-market strategy for pharma’s customer-facing teams can be challenging.

There are many issues to consider, from where the data originated and how up-to-date and complete it is to how and where it can really add value in better understanding and supporting customers.

It is also important to have the right platform on which to store the data and other supporting information, with metrics in place to monitor progress and inform decision-making.

Quality and relevance

Quality is a key criterion for data that must, of course, come from a trusted source. It should be validated and, if necessary, completed through further research to fill in any gaps. It is also important to note how frequently the sources are updated.

The next issue is relevance and when deciding what data to include in a strategic plan, it is worth getting a taskforce to review how it could be used, interpreted and combined to enable thoughtful Key Performance Indicators (KPIs) and analysis.

Also, ask end users to consider their business case and how data can help them deliver the right messages in conversations with customers.

Building datasets

The next step is to build data around the core segments of your plan, including key information on the customer’s organisation, its people and the clinical challenges it faces. What are its goals by therapy area and how is your company approaching them in terms of its activities, sales, formulary status, investments and relationships?

Look at the trends you want to track going forwards. For example, could you map trends among patients identified and treated in a particular therapy area versus the potential patient population that could be targeted?

It is also important to be open to change. So many great ideas have fallen by the wayside due to COVID-19, so take time to consider what needs to be reviewed and reinvigorated to get a return on investment.

Agility and analytics

Having determined the optimal mix of information to include within the go-to-market strategy, it is important to have the right platform in place to ensure that the data remains live and is supplemented with ongoing activities and other related information that support the customer-facing team.

Set measurements, KPIs and reporting that are user group specific and ensure that their value can be determined and shared across the whole organisation from development to marketing. Also, consider future pipeline needs and create building blocks of information that will be invaluable at launch.

Avoid overloading users with data and reports they do not need. Try to be as focused as possible, and ensure access to KPIs, charts and trackers are based on the users’ business plans, therapeutic focus and personal objectives, and are quick and easy to use.

Finally, keep an open mind about new data as it becomes available, challenge what you have built and allow users a direct channel for feedback. By constantly evolving your platform and sharing the right mix of real-time data across your organisation, you can provide a solid return on investment and deliver positive change as COVID-19 continues to pose unprecedented challenges to the healthcare industry.

For information on Wilmington Healthcare and its cloud-based strategic healthcare insight and strategic account management offerings, visit

Download our white paper: “Strategic thinking: how can data help to navigate the way ahead in 2021?”

Lisa Alderson is Business Development Director at Wilmington Healthcare

In association with

30th March 2021

From: Marketing


Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...